Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2020 3
2021 5
2022 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Treatment beyond progression with immune checkpoint inhibitors in non-small-cell lung cancer.
Reinhorn D, Jacobi O, Icht O, Dudnik E, Rotem O, Zer A, Goldstein DA. Reinhorn D, et al. Among authors: jacobi o. Immunotherapy. 2020 Mar;12(4):235-243. doi: 10.2217/imt-2019-0131. Epub 2020 Mar 19. Immunotherapy. 2020. PMID: 32189549
Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). ...Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with I …
Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint in …
Phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (cKS).
Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, Kurman N, Peretz I, Shamai S, Merimsky O, Ben-Ami E, Shapira Frommer R, Schwarzbach AE, Bernstine H, Weitzen R, Vornicova O, Bar-Sela G, Stemmer SM, Lotem M. Zer A, et al. Among authors: jacobi o. Ann Oncol. 2022 Jul;33(7):720-727. doi: 10.1016/j.annonc.2022.03.012. Epub 2022 Mar 23. Ann Oncol. 2022. PMID: 35339649 Free article. Clinical Trial.
Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.
Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G, Straussman R. Gavert N, et al. Among authors: jacobi o. Nat Cancer. 2022 Feb;3(2):219-231. doi: 10.1038/s43018-021-00325-2. Epub 2022 Feb 10. Nat Cancer. 2022. PMID: 35145327
Translating preclinical studies to effective treatment protocols and identifying specific therapeutic responses in individuals with cancer is challenging. This may arise due to the complex genetic makeup of tumor cells and the impact of their multifaceted tumor microenviro …
Translating preclinical studies to effective treatment protocols and identifying specific therapeutic responses in individuals with cance …
Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer.
Landman Y, Jacobi O, Kurman N, Yariv O, Peretz I, Rotem O, Dudnik E, Zer A, Allen AM. Landman Y, et al. Among authors: jacobi o. Oncoimmunology. 2021 Aug 10;10(1):1959979. doi: 10.1080/2162402X.2021.1959979. eCollection 2021. Oncoimmunology. 2021. PMID: 34408921 Free PMC article.
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although doses higher than 66 Gy are standard in our center, they were used in only 6.9% of patients in the PACIFIC trial. ...
The standard of care for stage III non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) followed by durvalumab. Although dos …
Antibody targeting of cell-bound MUC1 SEA domain kills tumor cells.
Pichinuk E, Benhar I, Jacobi O, Chalik M, Weiss L, Ziv R, Sympson C, Karwa A, Smorodinsky NI, Rubinstein DB, Wreschner DH. Pichinuk E, et al. Among authors: jacobi o. Cancer Res. 2012 Jul 1;72(13):3324-36. doi: 10.1158/0008-5472.CAN-12-0067. Epub 2012 Apr 16. Cancer Res. 2012. PMID: 22507854
The cell-surface glycoprotein MUC1 is a particularly appealing target for antibody targeting, being selectively overexpressed in many types of cancers and a high proportion of cancer stem-like cells. However the occurrence of MUC1 cleavage, which leads to the releas …
The cell-surface glycoprotein MUC1 is a particularly appealing target for antibody targeting, being selectively overexpressed in many types …
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O, Darzi N, Shimony S, Jacobi O, Reinhorn D, Landman Y, Mutai R, Averbuch I, Shochat T, Spectre G, Raanani P, Rotem O, Dudnik E, Peled N, Zer A, Leader A. Icht O, et al. Among authors: jacobi o. J Thromb Haemost. 2021 May;19(5):1250-1258. doi: 10.1111/jth.15272. Epub 2021 Mar 16. J Thromb Haemost. 2021. PMID: 33605020 Free article.
BACKGROUND: There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICI). The Khorana Score (KS), used to guide thromboprophylaxis in cancer patients, was validated in p …
BACKGROUND: There are scarce data on venous thromboembolism (VTE) rates among non-small cell lung cancer (NSCLC) patients treated wit …
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Jacobi O, Landman Y, Reinhorn D, Icht O, Sternschuss M, Rotem O, Finkel I, Allen AM, Dudnik E, Goldstein DA, Zer A. Jacobi O, et al. Oncology. 2021;99(9):555-561. doi: 10.1159/000516671. Epub 2021 Jul 9. Oncology. 2021. PMID: 34247166
Metformin, previously associated with improved chemotherapy efficacy in diabetic and nondiabetic cancer patients, was recently associated with increased ICI efficacy. In this study, we aimed to explore the correlations between diabetes mellitus (DM), metformin use, and ben …
Metformin, previously associated with improved chemotherapy efficacy in diabetic and nondiabetic cancer patients, was recently associ …
Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer.
Icht O, Domachevsky L, Groshar D, Dudnik E, Rotem O, Allen AM, Peled N, Reinhorn D, Jacobi O, Shochat T, Bernstine H, Zer A. Icht O, et al. Among authors: jacobi o. Asia Pac J Clin Oncol. 2021 Apr;17(2):e125-e131. doi: 10.1111/ajco.13360. Epub 2020 Aug 6. Asia Pac J Clin Oncol. 2021. PMID: 32762128
AIM: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment for advanced non-small-cell lung cancer (NSCLC), yet many patients do not benefit from Programmed cell death protein 1 (PD-1) axis inhibitors, emphasizing the need for additional markers for better …
AIM: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment for advanced non-small-cell lung cancer (NSCLC), yet many …
MUC1-ARF-A Novel MUC1 Protein That Resides in the Nucleus and Is Expressed by Alternate Reading Frame Translation of MUC1 mRNA.
Chalick M, Jacobi O, Pichinuk E, Garbar C, Bensussan A, Meeker A, Ziv R, Zehavi T, Smorodinsky NI, Hilkens J, Hanisch FG, Rubinstein DB, Wreschner DH. Chalick M, et al. Among authors: jacobi o. PLoS One. 2016 Oct 21;11(10):e0165031. doi: 10.1371/journal.pone.0165031. eCollection 2016. PLoS One. 2016. PMID: 27768738 Free PMC article.
While the malignant epithelial cells of pancreatic cancer show limited expression, in breast cancer tissue MUC1-ARF demonstrates strong nuclear expression. ...
While the malignant epithelial cells of pancreatic cancer show limited expression, in breast cancer tissue MUC1-ARF demonstrat …